comprehensive -WSS

comprehensive

author：fashion 2025-10-02 00:41:08 - browse：45687

On Tuesday, Google DeepMind and Isomorphic Labs announced a significant progress update on the next iteration of AlphaFold, the deep learning model that in 2020 cracked the problem of predicting a protein’s structure from its amino acid sequence, leapfrogging other approaches in computational biology.

Now, the companies say they have developed the model to predict not just standalone protein structures, but what proteins look like in combination with several classes of molecules, including small molecules and nucleic acids — capabilities that are key for drug development.

“We really needed to make progress on protein-ligand binding and co-folding of ligands with proteins in order to help us design more effective drugs,” said Demis Hassabis, CEO of both DeepMind and Isomorphic Labs, which spun out in 2021 with the goal of applying deep learning approaches to drug discovery. The updated model can also predict protein structures after they’ve been modified. “Basically the new AlphaFold can cope with all of these different things, which is pretty amazing.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Why did Pfizer dish out millions for a Super Bowl ad?

WSS

A disappointing year of Humira biosimilars

Biden report: The neurospychology of memory and aging

CDC advisory panel says seniors 'may' get RSV vaccine

Radiation, mainstay of cancer treatment, begins a fade

In science, is the line between industry and academia shifting?

Industry veterans launch new biotech VC with $310M

entertainment

comprehensive

knowledge

Bright Health sells Medicare Advantage business to Molina

Neuroscience startup Neumora files for IPO

Medicare proposal to cover medical devices draws a mixed reaction

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Apple is now the first public company to be valued at $3 trillion

Diversity in medical illustrations gets boost from Chidiebere Ibe

Medicare details structure of new drug price negotiation program

Medical mystery: When a cough is not just a cough

Wildfire smoke exposes gaps in outdoor worker protections

Why did Pfizer dish out millions for a Super Bowl ad?

knowledge

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Biogen Alzheimer’s drug launch off to slow start

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

A disappointing year of Humira biosimilars

Medicare explains how it will choose drugs for negotiation

What do new weight loss drugs mean for bariatric surgery?

leisure time

knowledge

explore

hotspot